报价延迟最少15分钟:2025/08/26 00:19 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.10/-4.82
|
|
企业价值
473.17M
|
| 资产负债 |
|
每股账面净值
17.19
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
4.32M
|
|
每股收益
0.07
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/26 00:19 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, whichderives key revenue, Wholly-Owned Programs, and Controlled Founded Entities. |
